Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1
5-Year Impact Factor – 2.2
Scopus CiteScore – 3.4 (CiteScore Tracker 3.7)
Index Copernicus  – 161.11; MNiSW – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2019, vol. 28, nr 2, February, p. 179–184

doi: 10.17219/acem/79969

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

The importance of the Wnt/β-catenin pathway and LRP5 protein in bone metabolism of postmenopausal women

Adam Kamiński1,A,B,F, Monika Karasiewicz2,B,C,D,E, Anna Bogacz3,4,B,C,D,E, Karolina Dziekan3,B,C, Agnieszka Seremak-Mrozikiewicz5,6,A,F, Bogusław Czerny3,7,B,E

1 Department of Orthopedics and Traumatology, Independent Public Clinical Hospital No. 1, Pomeranian Medical University in Szczecin, Poland

2 Laboratory of International Health, Department of Preventive Medicine, Poznan University of Medical Sciences, Poland

3 Department of Stem Cells and Regenerative Medicine, Institute of Natural Fibres and Medicinal Plants, Plewiska, Poland

4 Department of Histocompatibility with Laboratory of Genetic Diagnostics, Regional Blood Center, Poznań, Poland

5 Division of Perinatology and Women’s Diseases, Poznan University of Medical Sciences, Poland

6 Department of Pharmacology and Phytochemistry, Institute of Natural Fibres and Medicinal Plants, Plewiska, Poland

7 Department of General Pharmacology and Pharmacoeconomics, Pomeranian Medical University in Szczecin, Poland

Abstract

Background. Postmenopausal osteoporosis is the most common metabolic bone disease among women. The Wnt signaling pathway has been known to be the critical regulator of osteoblastogenesis. Alterations in this mechanism may have consequences for bone remodeling in humans.
Objectives. The aim of the study was to evaluate the frequency of genotypes and alleles of single nucleotide polymorphism (SNP) rs4988321 and rs312009 of LRP5 in Polish postmenopausal women with osteopenia (n = 109) and osteoporosis (n = 333). Potential correlations between genetic polymorphisms, bone mineral density (BMD), risk for bone fractures, and other clinical parameters were analyzed.
Material and Methods. Genomic DNA was extracted from the blood samples and the sequence polymorphisms of LRP5 gene were detected using real-time polymerase chain reaction (RT-PCR) methods with melting curve analysis. We also calculated the odds ratio (OR) for the LRP5 genotypes and the alleles. Then, we evaluated the effect of the LRP5 polymorphism on T-score, Z-score, L2L4AM, L2L4YA, L2L4BMD, body mass index (BMI), and other clinical parameters.
Results. No statistically significant differences in the distribution of LRP5 rs312009 genotypes between the groups were observed. Furthermore, our findings indicate that there is no correlation between LRP5 genotypes and the clinical characteristics of women with osteopenia/osteoporosis. In contrast, there was an increased value of OR in heterozygotes for rs4988321, both in patients with osteopenia (OR = 1.47) and in those with osteoporosis (OR = 1.33). In our study, we were not able to calculate the OR parameter for the AA genotype due to its low prevalence in the population.
Conclusion. Our results suggest that the Val667Met LRP5 (rs312009) polymorphism may contribute to an elevated risk for fractures in postmenopausal Polish women.

Key words

bone mineral density, LRP5, postmenopausal women, osteoporosis

References (23)

  1. Sassi R, Sahli H, Souissi C, et al. Association of LRP5 genotypes with osteoporosis in Tunisian post-menopausal women. BMC Musculoskelet Disord. 2014;15:144.
  2. Maupin KA, Droscha CJ, Williams BO. A comprehensive overview of skeletal phenotypes associated with alterations in Wnt/β-catenin signaling in humans and mice. Bone Res. 2013;1(1):27–71.
  3. Lara-Castillo N, Johnson ML. LRP receptor family member associated bone disease. Rev Endocr Metab Disord. 2015;16(2):141–148.
  4. Costantini A, Mäkitie O. Value of rare low bone mass diseases for osteoporosis genetic. Bonekey Rep. 2016;5:773.
  5. Krishnan V, Bryant HU, Macdougald OA. Regulation of bone mass by Wnt signaling. J Clin Invest. 2006;116(5):1202–1209.
  6. Johnson ML. LRP5 and bone mass regulation: Where are we now? Bonekey Rep. 2012;1:1. doi: 10.1038/bonekey.2012
  7. Kato M, Patel MS, Levasseur R, et al. Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J Cell Biol. 2002;157(2):303–314.
  8. Babij P, Zhao W, Small C, et al. High bone mass in mice expressing a mutant LRP5 gene. J Bone Miner Res. 2003;18(6):960–974.
  9. Akhter MP, Wells DJ, Short SJ, et al. Bone biomechanical properties in LRP5 mutant mice. Bone. 2004;35(1):162–169.
  10. Liedert A, Röntgen V, Schinke T, et al. Osteoblast-specific Krm2 overexpression and Lrp5 deficiency have different effects on fracture healing in mice. PloS One. 2014;9(7):e103250.
  11. Burgers TA, Williams BO. Regulation of Wnt/β-catenin signaling within and from osteocytes. Bone. 2013;54(2):244–249.
  12. Wolski H, Drwęska-Matelska N, Seremak-Mrozikiewicz A, Lowicki Z, Czerny B. The role of Wnt/β-catenin pathway and LRP5 protein in metabolism of bone tissue and osteoporosis etiology [in Polish]. Ginekol Pol. 2015;86(4):311–314.
  13. Zhang YP, Deng FY, Chen Y, et al. Replication study of candidate genes/loci associated with osteoporosis based on genome-wide screening. Osteoporos Int. 2010;21(5):785–795.
  14. van Meurs JB, Trikalinos TA, Ralston SH, et al. GENOMOS Study. Large-scale analysis of association between LRP5 and LRP6 variants and osteoporosis. JAMA. 2008;299(11):1277–1290.
  15. Van Hul E, Gram J, Bollerslev J, et al. Localization of gene causing autosomal dominant osteoporosis type I to chromosome 11q12-13. J Bone Miner Res. 2002;17(6):1111–1117.
  16. Agueda L, Bustamante M, Jurado S. A haplotype-based analysis of the LRP5 gene in relation to osteoporosis phenotypes in Spanish postmenopausal women. J Bone Miner Res. 2008;23(12):1954–1963.
  17. Agueda L, Velázquez-Cruz R, Urreizti R, et al. Functional relevance of the BMD-associated polymorphism rs312009: Novel involvement of RUNX2 in LRP5 transcriptional regulation. J Bone Miner Res. 2011;26(5): 1133–1144.
  18. Panach L, Mifsut D, Tarin JJ, Cano A, García-Pérez MÁ. Replication study of three functional polymorphisms associated with bone mineral density in a cohort of Spanish women. J Bone Miner Metab. 2014; 32(6):691–698.
  19. Stathopoulou MG, Dedoussis GV, Trovas G, et al. Low-density lipoprotein receptor-related protein 5 polymorphisms are associated with bone mineral density in Greek postmenopausal women: An interaction with calcium intake. J Am Diet Assoc. 2010;110(7):1078–1083.
  20. Falcon-Ramirez E, Casas-Avila L, Cerda-Flores RM, et al. Association of LRP5 haplotypes with osteoporosis in Mexican women. Mol Biol Rep. 2013;40(3):2705–2710.
  21. Grundberg E, Lau EM, Lorentzon M, et al. Large-scale association study between two coding LRP5 gene polymorphisms and bone phenotypes and fractures in men. Osteoporos Int. 2008;19(6):829–837.
  22. Li WF, Hou SX, Yu B, Li MM, Férec C, Chen JM. Genetics of osteoporosis: Accelerating pace in gene identification and validation. Hum Genet. 2010;127(3):249–285.
  23. Kumar J, Swanberg M, McGuigan F, Callreus M, Gerdhem P, Akesson K. LRP4 association to bone properties and fracture and interaction with genes in the Wnt- and BMP signaling pathways. Bone. 2011;49(3):343–348.
© Wroclaw Medical University